Loading…
Early cancer-detection company developing the Galleri multi-cancer early detection blood test, spun off from Illumina.
Early cancer-detection company developing the Galleri multi-cancer early detection blood test, spun off from Illumina.
Sells Galleri as a lab-run blood test ordered by doctors, but most patients pay out of pocket because insurers and Medicare do not generally cover screening yet, so wider coverage depends on trial evidence and regulatory approval. Illumina spun it off in 2024 and no longer controls it.
Moat: narrow (data, IP / patents, scale). First-mover with a large proprietary genomic dataset in the nascent multi-cancer early-detection category.
Headquarters: Menlo Park, California, USA · Founded: 2016 · Employees: 910
Size GRAIL (GRAL) is a United States Health Care company (Medical Specialties) with a market value of $5.42B, the 1127th largest of 3,117 United States companies the cockpit tracks. Shares closed at $80.77 on 6 Nov 2026.
Performance Over six months the shares gained 66.6%, against +23.6% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 23.1% over the last twelve months (peer median +2.6%); the operating margin is -323.0% (peer median 15.1%).
Valuation It trades at 2.13× book value against a peer median of 4.43× (4th cheapest of 21).
Price implies The share price implies a return on equity of about 37.5%; GRAIL delivers -16.1%, so the price asks more than the business earns today.
Short interest Short interest is 18.3% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $165M | $147M | $126M | $93.1M | $55.5M |
| Revenue growth | — | +17% | +35% | +68% | — |
| Gross profit | -$61.1M | -$77.4M | -$78.0M | -$95.6M | -$116M |
| EBITDA | -$378M | -$378M | -$570M | -$638M | -$588M |
| Net income | -$392M | -$408M | -$2.03B | -$1.47B | -$5.40B |
| Free cash flow | -$296M | -$300M | -$582M | -$609M | -$584M |
| Capital expenditure | $1.41M | $909,000 | $5.21M | $12.9M | $22.9M |
| Total debt | $91.3M | $54.9M | $68.1M | $84.4M | $96.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| GRAIL GRAL | $5.42B | +67% | +23% | -16% | 2.13× | 37.5% |
| Guardant Health GH | $20.2B | +58% | +43% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GRAL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.2% | +10.3% | 9th lowest of 21 |
| 6-month return | +66.6% | +23.6% | 3rd highest of 21 |
| Return on equity | -16.1% | 10.5% | lowest of 21 |
| Price / book | 2.13× | 4.43× | 4th cheapest of 21 |
| ROE the price implies | 37.5% | 18.4% | 6th most demanding of 21 |
| ROE delivered | -16.1% | 11.2% | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -16% | 2.13× | 37.5% | -16.1% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 11% | 6.51× | 35.5% | 11.2% |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 10% | 2.99× | 16.9% | 9.8% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 10% | 2.87× | 13.0% | 9.5% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 16% | 4.10× | 29.3% | 15.5% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 32% | 11.73× | 27.7% | 31.9% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | -10% | 1.30× | 7.4% | n/a |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 20% | 5.71× | 39.9% | 19.8% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 31% | 6.66× | 32.6% | 31.1% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | -11% | 2.20× | 16.5% | -10.5% |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 27% | 6.24× | 75.2% | 27.0% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 8% | 4.77× | 38.1% | 7.7% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 22% | 5.01× | 19.8% | 22.2% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 2% | 1.62× | 8.9% | 1.6% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 1% | 2.00× | 15.6% | 1.4% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 6% | 2.49× | 15.1% | 6.0% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 9% | 2.19× | 10.3% | 8.7% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 8% | 5.84× | 41.6% | 8.0% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 20% | 5.04× | 12.5% | 19.9% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 33% | 8.82× | 130.0% | 33.0% |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 21% | 3.34× | 13.2% | 20.6% |